Jim Tananbaum is the chief executive officer of Foresite Capital. He established the company in 2011 as a private equity firm. The corporation identifies emerging leaders in the healthcare industry. The company is able to supply information, capital, and networks. According to Jim, he established Foresite Capital after gaining extensive experience as a healthcare entrepreneur. Jim has also served as an investment strategist for many years. Over the years, Tananbaum identified key success factors, which would be beneficial to entrepreneurs and companies. He posits that innovation and team work plays a pivotal role in enhancing the success of a firm.
To him, Foresite Capital seeks to understand and exploit the future of healthcare. This idea originated from realizing that the company could play an important role of guiding the next generation of leaders in the healthcare industry by providing them with capital, adequate information, and networks. Development of innovative healthcare products require more time and capital. Presently, Foresite Capital has invested in 77 healthcare firms in medical services, biopharmaceuticals, genomic sequencing, and diagnostics. Moreover, the corporation has invested in Aerie Pharmaceuticals, 10X Genomics, Aimmune Therapeutics, and Intarcia Therapeutics.
Jim spends his day by undertaking his office duties and brainstorming different ideas with the members of his group. He also attends meetings and makes calls to discuss about the existing portfolio updates. Additionally, Tananbaum loves networking with thought leaders. Jim Tananbaum notes that his family is his priority. He loves having dinner with them.
About Jim Tananbaum
Jim Tananbaum is the chief executive officer of Foresite Capital Management. Tananbaum has invested in over 21 successful healthcare firms such as Jazz Pharmaceuticals and Amira Pharmaceuticals. Previously, he served in various management positions at Theravance and GelTex Pharmaceuticals, which was later acquired by Genzyme.
In a report by Wired, Jim Tananbaum is a proud alumnus of Harvard Medical School where he earned his M.D. He is also a graduate of Harvard Business School where pursed his MBA. In addition. Jim holds B.S.E.E. from the prestigious Yale University. Notably, the executive has served on the advisory boards of Yale School of Engineering and Harvard-MIT HST program. The transformative leader works closely with renowned academicians such as George Whitesides, Rick Klausner, Roy Vagelos and Rick Levin.